Pfizer Inc. announced today that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.
[More]
An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.
[More]
Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
[More]
Research suggests that most victims of home-bred midges, mosquitoes, flies, bedbugs and fleas will get better without any treatment at all. The review in the Drug and Therapeutics Bulletin (DTB), which offers impartial advice to doctors, admits that getting bitten may be horribly uncomfortable but there is little evidence that over-the-counter remedies work. Putting a cold compress to relieve pain and swelling could be a better option say researchers. Medical help should clearly be sought if serious symptoms, such as infections or anaphylactic shock, developed the DTB added.
[More]
In a joint study, researchers at the Johns Hopkins Bloomberg School of Public Health and Arizona State University found evidence suggesting that a class of antibiotics previously banned by the U.S. government for poultry production is still in use. Results of the study were published March 21 in Environmental Science & Technology.
[More]
A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.
[More]
Holiday gatherings are festive fun, but it's not easy to be the life of the party when you're sniffling, sneezing and wheezing. From the host's overpowering perfume to the nuts in the snack bowl, holiday parties can be a challenge for people with allergies and asthma.
[More]
Updated public standards incorporating new tests for impurities as well as more modern technologies to help ensure the quality of over-the-counter (OTC) ingredients and products will be key areas of focus for a September 8-9, 2011, workshop co-sponsored by the U.S. Food & Drug Administration (FDA) and the U.S. Pharmacopeial Convention.
[More]
AMRI today reported financial and operating results for the second quarter ended June 30, 2011.
[More]
The summer is a great season for getting in shape. Whether by playing a sport, doing an aerobic exercise routine, or just returning to that familiar running path -- this is the time for activity.
[More]
A cellulose powder has been used increasingly for many years against allergic rhinitis. Still, there has been a shortage of scientific evidence for its efficacy in seasonal allergic rhinitis (hay fever), particularly in children. Now, however, scientists from the Sahlgrenska Academy and the Department of Plant and Environmental Sciences at the University of Gothenburg have proven that the cellulose powder reduces symptoms of seasonal allergic rhinitis in children, without any adverse effects.
[More]
British scientists warn that well known brands of hay fever tablets, painkillers and sleeping pills pose a previously unknown threat to elderly people’s health when taken together. Many are available over the counter at pharmacies as well as being prescribed by GPs, nurses and chemists they said.
[More]
Summer fun is in full swing, which coincides with an increase in bumps, bruises, scrapes and possibly worse. To keep kids safe, prevention and first-aid should be at the forefront of parents' minds this summer according to Dr. Karen Judy, Loyola University Health System pediatric safety expert and professor of pediatrics at Loyola University Chicago Stritch School of Medicine.
[More]
Meda presents new positive results from a Phase-III clinical trial of Dymista at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in Istanbul, Turkey.
[More]
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Cetirizine Hydrochloride Oral Solution, 1 mg/mL.
[More]
Fighting hay fever with a plant extract - this works, as was shown in a clinical study conducted by researchers of the Center of Allergy & Environment of Helmholtz Zentrum München and Technische Universität München.
[More]
Spring weather signals the start of many outdoor activities as people of all ages eagerly embrace the change in weather. Paul Prinz, MD, orthopaedic surgeon at Gottlieb Memorial Hospital, part of Loyola University Health System says, "Broken bones and fractures occur year 'round but the change in seasons always creates an increase of patients in our offices."
[More]
As part of its ongoing mission to protect public health, the U.S. Pharmacopeial Convention is working with the Food and Drug Administration and the Consumer Healthcare Products Association to update quality standards for widely used medicines and ingredients.
[More]
Meda announced today positive results from a Phase III clinical trial of Dymista, a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with seasonal allergic rhinitis.
[More]